收入保持高增长，主要受奥布替尼放量与交易首付款确认双重驱动2025 年Q3 公司实现营业收入3.84 亿 元（+38.09%），延续了今年以来的高增速，主要系奥布替尼销售收入持续增长以及公司与 ProliumBioscience Inc.达成授权许可的首付款所致。按产品分析，前三季度奥布替尼收入10.10 亿元 （+45.77%），延续了上半年以来的高增长，其中Q3 收入3.73 亿元。公司2025 年前三季度净亏损为 0.72 亿元，比上年同期亏损收窄74.78%，据公司官方公众号，凭借强劲的收入增长、严格的费用管理 和今年10 月初和Zenas 达成的重磅对外授权交易，公司2025 全年实现盈亏平衡，提前两年实现盈利目 标，为可持续盈利和加速全球化奠定良好的基础。 与Zenas 达成授权合作，加速奥布替尼全球化布局据公司官网及公告，2025 年10 月，公司与Zenas BioPharma 达成重大授权合作协议，Zenas 将获得奥布替尼在多发性硬化领域的全球开发和商业化权 益，以及奥布替尼在非肿瘤的其他治疗领域的开发与商业化权益。Zenas 还获得两款临床前分子的相关 权益。Zenas 将向公司支付1 ...

Investment Rating - The report maintains a positive outlook on the innovative drug sector, indicating a rebound and potential for further growth in the upcoming months [3][6]. Core Insights - The innovative drug sector is expected to see a rebound after previous adjustments, with significant catalysts anticipated in December and January. The results of the national medical insurance negotiations will be released in early December, which may impact the inclusion of domestic innovative drugs in the insurance catalog [3][14]. - The upcoming American Society of Hematology (ASH) conference from December 6-9 is highlighted as a key event, with multiple differentiated hematology products expected to present new data [3][4][42]. - The CXO sector shows a continuous upward trend, supported by the rapid growth of new orders and backlog, ensuring performance release in the next 1-2 years [4][53]. Summary by Sections Innovative Drugs - The report emphasizes the importance of focusing on dual/multi-target drugs for various cancers and chronic diseases, as well as opportunities in ADCs and small nucleic acid therapies [6][15]. - The report notes that the innovative drug financing data is showing marginal improvement, indicating a potential recovery in the sector [6][15]. Biologics - The report mentions positive preliminary results from the Phase II clinical trial of amycretin for Type 2 diabetes, suggesting continued monitoring of its clinical progress [4][46]. Medical Devices - The report highlights the emergence of innovative domestic medical devices, with expectations for profit margins to stabilize and improve as new products are approved [5]. Traditional Chinese Medicine & Pharmacies - The report suggests monitoring companies with strong brand power and good inventory management, such as China Resources Sanjiu and Jichuan Pharmaceutical, due to rising flu incidence [5]. Medical Services and Consumer Healthcare - The report discusses a collaboration between a traditional Chinese medicine group and a local health bureau to enhance the capabilities of grassroots medical services through technology [5]. Key Investment Targets - The report identifies key companies to watch, including Innovent Biologics, Kintor Pharmaceutical, and others in the innovative drug and medical device sectors [7].

（文章来源：每日经济新闻） 诺诚健华（688428.SH）11月28日在投资者互动平台表示，尊敬的投资者，您好！截至目前，公司暂无 自研药品于欧盟范围内获批及销售。感谢您的关注！ 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近两年是否出口欧盟国家？ ...

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 有投资者在互动平台向诺诚健华提问："请问贵公司近两年是否出口欧盟国家？" 针对上述提问，诺诚健华回应称："尊敬的投资者，您好！截至目前公司暂无自研药品于欧盟范围内获 批及销售。感谢您的关注！" 作者：公告君 ...

格隆汇11月28日丨诺诚健华(688428.SH)在投资者互动平台表示，截至目前公司暂无自研药品于欧盟范 围内获批及销售。 ...

Core Insights - Nocera Biopharma announced the completion of the first patient dosing in the global Phase II clinical trial of its novel TYK2 inhibitor Soficitinib (ICP-332) for the treatment of nodular prurigo [1][2] - Soficitinib is a highly selective oral TYK2 inhibitor developed for various T-cell related autoimmune diseases, with a strong focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The global market for nodular prurigo treatment is projected to grow from $2 billion in 2024 to $3 billion by 2034, with approximately 10 million patients affected worldwide [1] Company Developments - Nocera Biopharma's product pipeline covers ten autoimmune diseases, with a significant emphasis on dermatological diseases [2] - Soficitinib has demonstrated excellent efficacy and safety in Phase II clinical studies for moderate to severe atopic dermatitis, and the related research was featured in a prominent oral presentation at the American Academy of Dermatology annual meeting [2] - The company is accelerating global clinical development to provide innovative treatment solutions for more autoimmune patients [2]

Core Insights - Nocare Biopharma announced the completion of the first patient dosing in the global Phase II clinical trial of its novel TYK2 inhibitor, Soficitinib, for the treatment of nodular prurigo [1][2] - Soficitinib is designed to treat various T-cell related autoimmune diseases, with a strong focus on dermatological conditions such as atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1] - The global market for nodular prurigo treatment is projected to grow from $2 billion in 2024 to $3 billion by 2034, with approximately 10 million patients affected worldwide [1] Company Developments - Nocare Biopharma's product pipeline covers ten autoimmune diseases, with a significant emphasis on dermatological diseases [2] - Soficitinib has demonstrated excellent efficacy and safety in Phase II clinical studies for moderate to severe atopic dermatitis, and the research was selected for a prominent oral presentation at the American Academy of Dermatology annual meeting [2] - The company is accelerating its global clinical development to provide innovative treatment solutions for more autoimmune patients [2]

Core Viewpoint - The company announced the completion of the first patient dosing in a global Phase II clinical trial for its novel TYK2 inhibitor Soficitinib (ICP-332) aimed at treating nodular prurigo [1] Group 1: Product Development - Soficitinib is a highly efficient and selective oral TYK2 inhibitor developed by the company [1] - The drug is being developed for various T-cell related autoimmune diseases, with a strong focus on dermatological indications [1] Group 2: Market Potential - The current development strategy includes a deep focus on a wide range of skin-related conditions, including atopic dermatitis, vitiligo, nodular prurigo, and urticaria [1]

Core Viewpoint - Nocera Biopharma has seen significant stock price growth this year, with a 112.95% increase, indicating strong market performance and investor interest [2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and R&D services [2]. Stock Performance - As of November 27, the stock price reached 26.15 CNY per share, with a market capitalization of 46.145 billion CNY [1]. - The stock has experienced a recent increase of 8.19% over the last five trading days and a 14.69% increase over the last 20 days, although it has declined by 8.28% over the past 60 days [2]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.4149 million CNY, showing a 76.61% increase in losses compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing investor interest [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include: - Fuguo Precision Medical Flexible Allocation Mixed A, holding 12.1549 million shares, down 427,100 shares from the previous period [3]. - Wanjia Preferred, a new shareholder with 10 million shares [3]. - Ping An Medical Health Mixed A, also a new shareholder with 8.6266 million shares [3].

Core Viewpoint - Nocera Biopharma has seen a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth in the biopharmaceutical sector [1][2]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [2]. Stock Performance - The stock price of Nocera Biopharma has increased by 110.02% year-to-date, with a recent 6.66% rise over the last five trading days and a 12.28% increase over the last 20 days, although it has seen a 10.76% decline over the past 60 days [2]. - As of November 26, the stock was trading at 25.79 CNY per share, with a market capitalization of 45.51 billion CNY [1]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion CNY, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.41 million CNY, an improvement of 76.61% compared to the previous period [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 16,500, with no change in the average number of circulating shares per person [3]. - Notable changes in institutional holdings include a decrease in shares held by some funds and the entry of new shareholders, indicating a shift in investor interest [3].